Hepatitis C News and Research

Latest Hepatitis C News and Research

Echosens's Vibration Controlled Transient Elastography stands out at 46th EASL Congress

On the occasion of the 46th Congress of the European Association for the Study of the Liver, the VCTE(TM) (Vibration Controlled Transient Elastography) from Echosens stood out as a leading technique in the field. It is the only technique able to measure elasticity at a predetermined, controlled frequency (50 Hz), which is essential because elasticity increases as frequency increases.

22 Apr 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

Researchers discover new compound to fight against shingles

Researchers at the University of Georgia and Yale University have discovered a compound with the potential to be more effective than existing agents in treating the very painful blisters known as shingles-a condition that affects up to 30 percent of Americans, mostly elderly, and for which no specific treatment exists.

22 Apr 2011

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Six-and-a-half weeks after receiving the first hand transplant in the western United States, Emily Fennell is becoming so accustomed to her new right hand that she barely remembers when she didn't have one.

21 Apr 2011

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Merck and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the initiation of a Phase III clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.

21 Apr 2011

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.

21 Apr 2011

Biomagnetics signs agreement with LANL to develop validated TB biomarker assay

Biomagnetics Diagnostics Corp., (PINK SHEETS: BMGP) a developer of revolutionary diagnostic systems and related technology for detecting HIV, hepatitis, tuberculosis, cholera and malaria, and other innovative technologies, today announced it has now completed a series of payments to Los Alamos National Laboratory (LANL) pursuant to the cooperative research and development agreement (CRADA) executed in 2010 between the two organizations.

21 Apr 2011

BIOTECH Development Partners provides funds to Biomagnetics

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, cholera and malaria detection, and other innovative technologies, today announced it has begun receiving funds from a biotech-oriented investment group called BIOTECH Development Partners, LLC.

20 Apr 2011

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

On the heels of Centers for Disease Control announcement earlier today that an ongoing study of the use of Gilead's top selling AIDS treatment, Truvada, as a possible form of pre-exposure prophylaxis for HIV prevention in women is being abruptly halted because the, "…trial could not demonstrate efficacy," the AIDS Healthcare Foundation renewed its call on Gilead Sciences to slow its fast track pursuit of its application for FDA approval of use of its AIDS drug as a possible form of HIV prevention.

20 Apr 2011

Quest Diagnostics launches AccuType IL28B test for HCV

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced the availability of its AccuType® IL28B test for aiding in the prediction of patient response to peginterferon alpha-based therapy for hepatitis C virus (HCV) infection.

From Quest Diagnostics 18 Apr 2011

Idera's gene-silencing oligonucleotide studies published in Journal of Medicinal Chemistry

Idera Pharmaceuticals, Inc. today announced the online publication in the Journal of Medicinal Chemistry of its studies of a novel class of compounds, which we refer to as gene-silencing oligonucleotides.

18 Apr 2011

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study.

18 Apr 2011

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Amylin Pharmaceuticals, Inc. today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy.

16 Apr 2011

Depression can sabotage efforts to effectively treat Hepatitis C

Adherence to interferon, an important medication used to treat Hepatitis C, is critical to successfully clearing the virus that causes the disease. A new observational analysis by Medco Health Solutions, Inc. finds that when Hepatitis C patients are also being treated for depression -- a frequent side effect of interferon use -- they are more likely to remain on their interferon therapy.

12 Apr 2011

Study unravels how interferon-induced factors inhibit viruses

When viruses attack, one molecule more than any other fights back. Interferon triggers the activation of more than 350 genes, and despite the obvious connection, the vast majority have never been tested for antiviral properties.

11 Apr 2011

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, the independent Data Monitoring Committee recommended suspension of enrollment.

11 Apr 2011

Idenix prices underwritten registered public offering of 18 million shares of common stock

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 18,310,000 shares of its common stock at a public offering price of $2.80 per share. All of the shares are being sold by Idenix.

8 Apr 2011

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates resulted in significant reduction in lung tissue presence of leukocytes, and in particular, that of eosinophils in a lethal influenza infection animal model.

8 Apr 2011

Experimental Biology 2011 to be held April 9-13 in Washington, D.C.

The meeting Experimental Biology 2011 (EB 2011) begins April 9 and runs through April 13 at the Walter E. Washington Convention Center in Washington, D.C.

8 Apr 2011

HALT-C trial reveals high mortality rates among patients with HCV

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis.

8 Apr 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Echosens's Vibration Controlled Transient Elastography stands out at 46th EASL Congress

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Researchers discover new compound to fight against shingles

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Biomagnetics signs agreement with LANL to develop validated TB biomarker assay

BIOTECH Development Partners provides funds to Biomagnetics

FHI to stop FEM-PrEP study of HIV prevention among heterosexual women

Quest Diagnostics launches AccuType IL28B test for HCV

Idera's gene-silencing oligonucleotide studies published in Journal of Medicinal Chemistry

Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV

Amylin's new metreleptin data in lipodystrophy to be presented at AACE meeting

Depression can sabotage efforts to effectively treat Hepatitis C

Study unravels how interferon-induced factors inhibit viruses

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Idenix prices underwritten registered public offering of 18 million shares of common stock

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

Experimental Biology 2011 to be held April 9-13 in Washington, D.C.

HALT-C trial reveals high mortality rates among patients with HCV

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in